Interdisciplinary Training Network for Validation of Gram-negative Antibacterial Targets (H2020-MCSA-ITN-2014)

Project: Research project

Project Details

Description (abstract)

Antimicrobial resistance is posing a continuously-rising threat to global health. Indeed, one key recommendation from the recent “Action plan against the rising threats from Antimicrobial Resistance” report (submitted by the Commission to the
European Parliament and Council (15.11.2011)) is the development of effective antimicrobials or alternatives for treatment of human and animal infections. The INTEGRATE project is a direct response to this. We have assembled a team of 10
beneficiaries from eight EU member states, encompassing both academic and non-academic sectors and different disciplines, to form a consortium committed to training Early Stage Researchers (ESRs) in the discovery and preclinical validation of novel Gram-negative antibacterial agents and antibacterial targets. The principle aim of the consortium is to provide a training platform where students are exposed to every aspect of the antimicrobial discovery process, ranging from target identification and validation, through organic synthesis, in silico design and compound screening, to mode-of-action and possible resistance mechanisms. This exposure will be accomplished through a concrete secondment plan, coupled with a series of high-level consortium-wide training events and networking programmes. Our intention is to reverse the current fragmentation of approaches towards antibacterial discovery through mutual cooperation. The INTEGRATE training framework is built on an innovative research project aimed at targeting important but non-essential gene products as an effective means of reducing bacterial fitness, thereby facilitating clearance of the pathogen by the host immune system. To achieve this, the individual work programmes have been designed to seamlessly inter-mesh contributions from the fields of in silico design, organic synthesis, molecular biology and biochemistry, and the very latest in vitro and in vivo screening technologies.
Effective start/end date01/01/201531/12/2018


  • European Commission / Horizon 2020: €254,753.39

Fields of Science

  • 317 Pharmacy
  • Vanesa Garrido

    Päivi Tammela (Host)

    3 Apr 201831 May 2018

    Activity: Hosting a visitor typesAcademic visit at UH

  • Alyssa McVey

    Päivi Tammela (Host)

    5 Feb 201829 Mar 2018

    Activity: Hosting a visitor typesAcademic visit at UH


    Viviana Gatta (Visiting researcher)

    26 Feb 201823 Mar 2018

    Activity: Visiting an external institution typesAcademic visit to other institution